12/19
07:13 am
armp
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection [Yahoo! Finance]
Low
Report
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection [Yahoo! Finance]
12/19
07:00 am
armp
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Low
Report
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
11/19
07:06 am
armp
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting [Yahoo! Finance]
High
Report
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting [Yahoo! Finance]
11/19
07:00 am
armp
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
High
Report
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
11/13
07:22 pm
armp
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/13
04:22 pm
armp
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update [Yahoo! Finance]
11/13
04:05 pm
armp
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
Low
Report
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
11/12
07:00 am
armp
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
High
Report
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
10/30
07:00 am
armp
Armata Pharmaceuticals Announces Structural Biology Publication
Low
Report
Armata Pharmaceuticals Announces Structural Biology Publication